These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24505830)

  • 1. Exclusivity strategies and opportunities in view of the Biologics Price Competition and Innovation Act.
    Gaudry KS
    Food Drug Law J; 2011; 66(4):587-630, ii. PubMed ID: 24505830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new follow-on-biologics law: a section by section analysis of the patent litigation provisions in the Biologics Price Competition and Innovation Act of 2009.
    Dougherty MP
    Food Drug Law J; 2010; 65(2):231-45, i. PubMed ID: 24475541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The constitutional protection of trade secrets and patents under the Biologics Price Competition and Innovation Act of 2009.
    Epstein RA
    Food Drug Law J; 2011; 66(3):285-328. PubMed ID: 24505851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C
    Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.
    Grabowski HG; Kyle M; Mortimer R; Long G; Kirson N
    Health Aff (Millwood); 2011 Nov; 30(11):2157-66. PubMed ID: 22068409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars: impact of differences with Hatch-Waxman.
    Kowalchyk K; Crowley-Weber C
    Pharm Pat Anal; 2013 Jan; 2(1):29-37. PubMed ID: 24236968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patent Cliffs in the Era of Complex Therapies and Biologics.
    Sabatini MT; Silva M
    Pharmaceut Med; 2020 Aug; 34(4):271-278. PubMed ID: 32772314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP; Singh SC; Brennan TA
    Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hatch-Waxman Act: encouraging innovation and generic drug competition.
    Sokal AM; Gerstenblith BA
    Curr Top Med Chem; 2010; 10(18):1950-9. PubMed ID: 20615183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teva v. Eisai: what's the real "controversy"?
    Wang GL
    Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategic considerations under the Biologics Price Competition and Innovation Act.
    Marquardt JL; Auten SR
    Expert Opin Ther Pat; 2013 Aug; 23(8):915-8. PubMed ID: 23829693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL
    Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decade.
    Grabowski H; Vernon J
    Pharmacoeconomics; 1996; 10 Suppl 2():110-23. PubMed ID: 10163428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study.
    Lexchin J
    Value Health; 2017 Sep; 20(8):1139-1142. PubMed ID: 28964446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repercussions of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Hogan GF
    Am J Hosp Pharm; 1985 Apr; 42(4):849-51. PubMed ID: 4014238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new history and discussion of 180-day exclusivity.
    Korn DE; Lietzan E; Scott SW
    Food Drug Law J; 2009; 64(2):335-90. PubMed ID: 19999288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
    Rea TS
    Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713
    [No Abstract]   [Full Text] [Related]  

  • 20. Using Data Exclusivity Grants to Incentivize Cumulative Innovation of Biologics' Manufacturing Processes.
    Levi EL
    Am Univ Law Rev; 2017; 66(3):911-70. PubMed ID: 28233970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.